| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
95%
|
USAspending awards from Department of Veterans Affairs: $459,591 across 2 awards. 36C25025P0648 PHARMACY PHARMACEUTICAL DRUG; 36C25025P1221 CTESI (CHENODIOL) 250MG DRUG | Qwen corrected direction: Ex… |
| NOVARTIS-PHARMA-AG |
NOVARTIS-PHARMA-AG |
85%
|
ight-of-use asset 1,113 Other non-current assets 3,888 Total assets acquired $ 789,896 Liabilities assumed: Accounts payable 1,589 Accrued expenses and other current liabilities 16,616 Operating leas… |
| NVS |
Novartis AG |
85%
|
Reciprocal relationship from NVS graph: Reciprocal relationship from MIRM graph: ight-of-use asset 1,113 Other non-current assets 3,888 Total assets acquired $ 789,896 Liabilities assumed: Accounts p… |
| CMMB |
Chemomab Therapeutics Ltd. |
72%
|
Reciprocal relationship from CMMB graph: Reciprocal relationship from MIRM graph: Reciprocal relationship from CMMB graph: Reciprocal relationship from MIRM graph: Reciprocal relationship from CMMB g… |
| CMMB |
Chemomab Therapeutics Ltd. |
72%
|
with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regula… |
| ORANY |
ORANY |
72%
|
with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regula… |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from MIRM graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from MIRM graph: with such services. Under certain… |
| PRQR |
ProQR Therapeutics N.V. |
72%
|
Reciprocal relationship from PRQR graph: Reciprocal relationship from MIRM graph: Reciprocal relationship from PRQR graph: Reciprocal relationship from MIRM graph: Reciprocal relationship from PRQR g… |
| PRQR |
ProQR Therapeutics N.V. |
72%
|
with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regula… |
| SNYNF |
Sanofi |
72%
|
nt was recorded for the years ended December 31, 2025 and 2024. In April 2023, the Company exercised the Call Option and repurchased all future Revenue Interests. In connection with such repurchase, … |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from MIRM graph: nt was recorded for the years ended December 31, 2025 and 2024. In April 2023, the Company exercised the Call Option… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from MIRM graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from MIRM graph: nt was recorded for the years end… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
nt was recorded for the years ended December 31, 2025 and 2024. In April 2023, the Company exercised the Call Option and repurchased all future Revenue Interests. In connection with such repurchase, … |
| TVTX |
Travere Therapeutics, Inc. |
72%
|
Reciprocal relationship from TVTX graph: Reciprocal relationship from MIRM graph: nt was recorded for the years ended December 31, 2025 and 2024. In April 2023, the Company exercised the Call Option … |
| TVTX |
Travere Therapeutics, Inc. |
72%
|
nt was recorded for the years ended December 31, 2025 and 2024. In April 2023, the Company exercised the Call Option and repurchased all future Revenue Interests. In connection with such repurchase, … |
| ANNORA-PHARMA-PRIVATE-LIMITED-HETERO-LABS-LIMITE |
ANNORA-PHARMA-PRIVATE-LIMITED-HETERO-LABS-LIMITE |
62%
|
with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regula… |
| BLUEJAY-THERAPEUTICS-INC |
BLUEJAY-THERAPEUTICS-INC |
62%
|
zed Loss Estimated Fair Value Cash equivalents and investments: Money market funds $ 254,376 $ — $ — $ 254,376 Corporate debt securities 72,170 107 — 72,277 U.S. government bonds 16,984 32 — 17,016 C… |
| CANBRIDGE-PHARMACEUTICALS-INC |
CANBRIDGE-PHARMACEUTICALS-INC |
62%
|
ot paid milestone payments pursuant to this agreement for the periods presented. In May 2022, the Company completed the merger and acquisition of Satiogen for total consideration of approximately $ 2… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
n not that the asset is impaired. If it is determined that the asset is impaired, the carrying value is written down to its estimated fair value, with the related impairment charge recognized in the … |
| DART-NEUROSCIENCE-LLC |
DART-NEUROSCIENCE-LLC |
62%
|
,090 ) Balance at December 31, 2023 $ — $ — The net loss from termination of the RIPA of $ 49.1 million, comprised of the $ 50.2 million loss related to the settlement of the revenue interest liabili… |
| ENTHORIN-THERAPEUTICS-LLC |
ENTHORIN-THERAPEUTICS-LLC |
62%
|
,090 ) Balance at December 31, 2023 $ — $ — The net loss from termination of the RIPA of $ 49.1 million, comprised of the $ 50.2 million loss related to the settlement of the revenue interest liabili… |
| HETERO-USA-INC |
HETERO-USA-INC |
62%
|
with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regula… |
| LEERINK-PARTNERS-LLC |
LEERINK-PARTNERS-LLC |
62%
|
lopment expenses, including with respect to increased costs associated with APIs and raw materials. Trade restrictions affecting the import of materials necessary for clinical trials could result in … |
| SANOFI-AVENTIS-DEUTSCHLAND-GMBH |
SANOFI-AVENTIS-DEUTSCHLAND-GMBH |
62%
|
d commercialization of the Bile Acid Medicines. The Company paid $ 210.4 million upon closing of the transaction, and up to an additional $ 235.0 million is payable upon the achievement of certain mi… |
| SATIOGEN-PFIZER-INC |
SATIOGEN-PFIZER-INC |
62%
|
d commercialization of the Bile Acid Medicines. The Company paid $ 210.4 million upon closing of the transaction, and up to an additional $ 235.0 million is payable upon the achievement of certain mi… |
| SATIOGEN-PHARMACEUTICALS-INC |
SATIOGEN-PHARMACEUTICALS-INC |
62%
|
with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regula… |
| SHIRE-HUMAN-GENETIC-THERAPIES-INC |
SHIRE-HUMAN-GENETIC-THERAPIES-INC |
62%
|
with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regula… |
| SHIRE-INTERNATIONAL-GMBH |
SHIRE-INTERNATIONAL-GMBH |
62%
|
d commercialization of the Bile Acid Medicines. The Company paid $ 210.4 million upon closing of the transaction, and up to an additional $ 235.0 million is payable upon the achievement of certain mi… |
| U-S-BANK-TRUST-COMPANY |
U-S-BANK-TRUST-COMPANY |
62%
|
lopment expenses, including with respect to increased costs associated with APIs and raw materials. Trade restrictions affecting the import of materials necessary for clinical trials could result in … |
| ZENARA-PHARMA-PRIVATE-LIMITED |
ZENARA-PHARMA-PRIVATE-LIMITED |
62%
|
with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regula… |
